Analysts take a look at Magellan Health Inc (NASDAQ:MGLN) having this to say.

June 19, 2017 - By Henry Gaston

 Analysts take a look at Magellan Health Inc (NASDAQ:MGLN) having this to say.
Investors sentiment increased to 0.97 in Q4 2016. Its up 0.06, from 0.91 in 2016Q3. It is positive, as 14 investors sold Magellan Health Inc shares while 81 reduced holdings. 40 funds opened positions while 52 raised stakes. 21.43 million shares or 3.41% more from 20.72 million shares in 2016Q3 were reported.
Susquehanna Llp invested 0% of its portfolio in Magellan Health Inc (NASDAQ:MGLN). Aqr Cap Management Ltd Limited Liability Company accumulated 49,752 shares. Pub Sector Pension Invest Board reported 16,512 shares. State Teachers Retirement Systems stated it has 65,407 shares. Clark Group Inc Inc has invested 0.06% of its portfolio in Magellan Health Inc (NASDAQ:MGLN). 421,200 are owned by Prudential Public Ltd. Commercial Bank Of New York Mellon Corp invested in 305,988 shares or 0.01% of the stock. Profund Limited Com invested in 0.02% or 6,263 shares. Qs Ltd Company reported 0.09% in Magellan Health Inc (NASDAQ:MGLN). Arizona State Retirement Systems holds 0.01% or 12,012 shares in its portfolio. Deutsche Bank Ag reported 70,952 shares stake. Moreover, Loomis Sayles & Company Limited Partnership has 0% invested in Magellan Health Inc (NASDAQ:MGLN). Guggenheim Capital Ltd Liability Com accumulated 29,759 shares. Rhumbline Advisers holds 0.01% or 38,335 shares in its portfolio. Blackrock Advsrs Limited Company holds 30,756 shares or 0% of its portfolio.

Since February 1, 2017, it had 0 insider buys, and 4 selling transactions for $2.88 million activity. WEST JEFFREY N also sold $1.09M worth of Magellan Health Inc (NASDAQ:MGLN) shares. On Thursday, February 23 the insider BROSHY ERAN sold $389,360.

Magellan Health Inc (NASDAQ:MGLN) Ratings Coverage

Among 3 analysts covering Magellan Health (NASDAQ:MGLN), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Magellan Health had 11 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Underweight” rating by Barclays Capital given on Wednesday, November 23. The stock of Magellan Health Inc (NASDAQ:MGLN) earned “Sector Perform” rating by Scotia Capital on Tuesday, August 11. On Wednesday, January 6 the stock rating was downgraded by Barclays Capital to “Underweight”. As per Monday, September 26, the company rating was maintained by Jefferies. Jefferies maintained it with “Buy” rating and $86 target in Friday, May 20 report. Below is a list of Magellan Health Inc (NASDAQ:MGLN) latest ratings and price target changes.

About 14,680 shares traded. Magellan Health Inc (NASDAQ:MGLN) has risen 5.31% since June 19, 2016 and is uptrending. It has underperformed by 11.39% the S&P500.

Magellan Health, Inc. is engaged in the healthcare management business. The company has market cap of $1.74 billion. The Company’s divisions include Healthcare, Pharmacy Management and Corporate. It has a 21.17 P/E ratio. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare.

More notable recent Magellan Health Inc (NASDAQ:MGLN) news were published by: Seekingalpha.com which released: “Magellan Health Services’ (MGLN) CEO Barry Smith on Q1 2017 Results – Earnings …” on April 26, 2017, also Zacks.com with their article: “3 Reasons Value Stock Investors Will Love Magellan Health (MGLN)” published on December 20, 2016, Businesswire.com published: “Magellan Behavioral Health of Pennsylvania, Inc. Earns Full Accreditation from …” on March 23, 2017. More interesting news about Magellan Health Inc (NASDAQ:MGLN) were released by: Businesswire.com and their article: “Magellan Health Reports Third Quarter 2016 Financial Results” published on November 09, 2016 as well as Businesswire.com‘s news article titled: “Magellan Rx Management Earns URAC Reaccreditation in Pharmacy Benefit Management” with publication date: April 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.